Praxis Precision Heading for 'Exciting' 2026, Truist Says

MT Newswires Live04:23

Praxis Precision Medicines (PRAX) is set for "exciting" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.

The note said securing the label is a positive "surprise" because there is an approved drug for essential tremor, propranolol.

"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority," the report said.

The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.

The report also pointed to indication of FDA's "comfort" with the data and pre-new drug application meeting.

"All of the above de-risk forthcoming NDA submission in early 2026," the note said. Truist kept its high conviction buy rating.

Price: 302.97, Change: +34.02, Percent Change: +12.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595730205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595730205","market":"fut","top_or_hot":-1,"title":"Praxis Precision Heading for 'Exciting' 2026, Truist Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> (PRAX) is set for \"exciting\" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.</p><p>The note said securing the label is a positive \"surprise\" because there is an approved drug for essential tremor, propranolol.</p><p>\"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority,\" the report said.</p><p>The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.</p><p>The report also pointed to indication of FDA's \"comfort\" with the data and pre-new drug application meeting.</p><p>\"All of the above de-risk forthcoming NDA submission in early 2026,\" the note said. Truist kept its high conviction buy rating.</p><p>Price: 302.97, Change: +34.02, Percent Change: +12.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Heading for 'Exciting' 2026, Truist Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Heading for 'Exciting' 2026, Truist Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-30 04:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> (PRAX) is set for \"exciting\" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.</p><p>The note said securing the label is a positive \"surprise\" because there is an approved drug for essential tremor, propranolol.</p><p>\"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority,\" the report said.</p><p>The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.</p><p>The report also pointed to indication of FDA's \"comfort\" with the data and pre-new drug application meeting.</p><p>\"All of the above de-risk forthcoming NDA submission in early 2026,\" the note said. Truist kept its high conviction buy rating.</p><p>Price: 302.97, Change: +34.02, Percent Change: +12.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2595730205","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595730205","pubTimestamp":1767039812,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Praxis Precision Medicines  is set for \"exciting\" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.The note said securing the label is a positive \"surprise\" because there is an approved drug for essential tremor, propranolol.\"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority,\" the report said.The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.The report also pointed to indication of FDA's \"comfort\" with the data and pre-new drug application meeting.\"All of the above de-risk forthcoming NDA submission in early 2026,\" the note said. Truist kept its high conviction buy rating.Price: 302.97, Change: +34.02, Percen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","PRAX":"Praxis Precision Medicines, Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Truist表示，Praxis Precision将迈向“激动人心”的2026年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"Praxis Precision Medicines (PRAX) is set for \"exciting\" 2026 after securing a Breakthrough Therapy Designation for ulixacaltamide in essential tremor, Truist Securities said in a note Monday.The note said securing the label is a positive \"surprise\" because there is an approved drug for essential tremor, propranolol.\"Therefore, to be granted BTD despite the availability of a commercial drug...implies high unmet need in ET and at least some perception of ulixa's superiority,\" the report said.The label is typically granted during earlier stages of drug development, the note said. For ulixa to obtain it after trial results imply that the FDA decision may have been based, at least in part, on the positive trial results, it added.The report also pointed to indication of FDA's \"comfort\" with the data and pre-new drug application meeting.\"All of the above de-risk forthcoming NDA submission in early 2026,\" the note said. Truist kept its high conviction buy rating.Price: 302.97, Change: +34.02, Percent Change: +12.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595730205","isCrawlerRequest":true}